Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.54 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939611 | 0.90 | SMYD3 (0.59) | MAPTKDM4EALDH1A1CRBNSMYD3 | |
| SCHEMBL29995492 | 0.90 | SMYD3 (0.59) | MAPTKDM4EALDH1A1CRBNSMYD3 | |
| Succinimide SCHEMBL9294241 | 0.89 | SMYD3 (0.58) | MAPTKDM4EALDH1A1CRBNSMYD3 | |
| Bicarbonate SCHEMBL11126587 | 0.83 | GSK3B (0.52) | MAPTKDM4ECRBNSMYD3AKR1C4 | |
| SCHEMBL10760242 | 0.82 | GSK3B (0.54) | MAPTKDM4ECRBNSMYD3AKR1C4 | |
| SCHEMBL7525379 | 0.82 | CRBN (0.64) | MAPTALDH1A1CRBNSMYD3HTT | |
| SCHEMBL29003155 | 0.82 | AKR1C4 (0.51) | MAPTKDM4ECRBNSMYD3AKR1C4 | |
| SCHEMBL5467106 | 0.82 | MAPT (0.52) | MAPTKDM4EALDH1A1CRBNSMYD3 | |
| SCHEMBL688890 | 0.81 | TDP2 (0.61) | MAPTKDM4ESMYD3HTTTDP2 | |
| SCHEMBL10648027 | 0.81 | KMO (0.48) | MAPTKDM4EALDH1A1CRBNSMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2015-06-18 | — | — | US | disclosed |
| US-8933109-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA LIMITED (GB) | 2015-01-13 | — | — | US | disclosed |
| US-20140038944-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-8552202-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2013-10-08 | — | — | US | disclosed |
| US-20130150345-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| US-8389737-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| EP-2297162-B1 | COMPOUNDS | AMURA THERAPEUTICS LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| EP-2283022-B1 | FURO [3, 2-B]PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-07-18 | — | — | EP | disclosed |
| US-8008290-B2 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2011-08-30 | — | — | US | disclosed |
| EP-2297162-A1 | COMPOUNDS | Amura Therapeutics Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| EP-2283022-A1 | FURO Ý3, 2-B¨PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | Amura Therapeutics Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| US-20110009385-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| WO-2009144450-A1 | TETRAHYDROFURO [3, 2-B] PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009112826-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112839-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150345-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | MAPT 4162/4885KDM4E 4450/4885ALDH1A1 4265/4885 |
| US-20110009385-A1 | COMPOUNDS | CTSK, CTSS, MMP9 | MAPT 3024/4885KDM4E 3972/4885ALDH1A1 2263/4885 |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | MAPT 3942/4885KDM4E 4509/4885ALDH1A1 3819/4885 |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | MAPT 4162/4885KDM4E 4450/4885ALDH1A1 4265/4885 |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | MAPT 4162/4885KDM4E 4450/4885ALDH1A1 4265/4885 |
| US-20140038944-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | MAPT 4162/4885KDM4E 4450/4885ALDH1A1 4265/4885 |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | MAPT 3942/4885KDM4E 4509/4885ALDH1A1 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.